Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Items 501–600 of 1,003
Dual-Network Collaborative Matrix Factorization for predicting small molecule-miRNA associations
Wang, S., Wang, C.-C., Li, H., Miao, L., & Chen, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab500 · Cited by 47
From Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 46
HTS assays for developing the molecular pharmacology of ion channels
McManus, O. B. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.01.004 · Cited by 47
“Such methods may identify compounds with novel mechanisms, but face challenges in modulating protein–protein interactions in assembled proteins [9].”
BackgroundStructural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development
Duran‐Frigola, M., Mosca, R., & Aloy, P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.004 · Cited by 51
Ballatore, C., R. Brunden, K., Q. Trojanowski, J., M.-Y. Lee, V., B. Smith, A., & M. Huryn, D. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611794072605 · Cited by 44
“Furthermore, a growing number of protein-protein interactions are considered to be potentially druggable targets [3,4,8].”
BackgroundIntracellular antibodies and cancer: New technologies offer therapeutic opportunities
Pérez-Martínez, D., Tanaka, T. U., & Rabbitts, T. H. (2010) · BioEssays · doi:10.1002/bies.201000009 · Cited by 50
“Protein-protein interactions are generally considered undruggable [1] because of their relatively featureless flat and extensive interfaces, although recent developments are changing this pattern of thought [2, 3].”
BackgroundA Small‐Molecule Protein–Protein Interaction Inhibitor of PARP1 That Targets Its BRCT Domain
Na, Z., Peng, B., Ng, S., Pan, S., Lee, J., Shen, H., & Yao, S. Q. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410678 · Cited by 51
Knauer, S. K., Moodt, S., Berg, T., Liebel, U., Pepperkok, R., & Stauber, R. H. (2005) · Traffic · doi:10.1111/j.1600-0854.2005.00298.x · Cited by 44
“In addition, it has been acknowledged that molecules, which modulate protein–protein interactions may have great potential as therapeutics (40).”
BackgroundSimeonov, A. M., Yasgar, A., Jadhav, A., Lokesh, G. L.-R., Klumpp-Thomas, C. A., Michael, S., Austin, C. P., Natarajan, A., & Inglese, J. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.11.039 · Cited by 50
“For example, colloidal aggregates spontaneously formed by certain compounds might reach the size and topology sufficient to perturb PPIs in a reproducible yet nonspecific and biologically irrelevant manner [2,4,5].”
InfluentialAndreoli, M., Persico, M., Kumar, A., Orteca, N., Kumar, V., Pepe, A., Mahalingam, S. M., Alegría, A. E., Petrella, L., Sevciunaite, L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5009902 · Cited by 48
Kahsai, A. W., Zhu, S., Wardrop, D. J., Lane, W. S., & Fenteany, G. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.07.011 · Cited by 44
Mukhopadhyay, A., Ray, S., & Maulik, U. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-26 · Cited by 43
“Recently, PPI prediction has been regarded as an promising alternative to the traditional approach to drug design [1].”
Design and Facile Solid-Phase Synthesis of Conformationally Constrained Bicyclic Peptoids
Lee, J. H., Kim, H. S., & Lim, H. (2011) · Organic Letters · doi:10.1021/ol201773f · Cited by 43
Cheng, H., Li, X., Wang, C., Chen, Y., Li, S., Tan, J., Tan, B., & He, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.013 · Cited by 43
Scanning Protein Surfaces with DNA‐Encoded Libraries
Kunig, V. B. K., Potowski, M., Škopić, M. K., & Brunschweiger, A. (2020) · ChemMedChem · doi:10.1002/cmdc.202000869 · Cited by 54
Yamgar, R., Nivid, Y., Nalawade, S. M., Mandewale, M. C., Atram, R. G., & Sawant, S. S. (2014) · Bioinorganic Chemistry and Applications · doi:10.1155/2014/276598 · Cited by 43
“Some can inhibit a specific function of a multifunctional protein or disrupt protein-protein interactions [5].”
Background“Bio”‐Macromolecules: Polymer‐Protein Conjugates as Emerging Scaffolds for Therapeutics
Borchmann, D. E., Carberry, T. P., & Weck, M. (2013) · Macromolecular Rapid Communications · doi:10.1002/marc.201300792 · Cited by 45
Mattila, E., Marttila, H., Sahlberg, N., Kohonen, P. J., Tähtinen, S., Halonen, P., Perälä, M., & Ivaska, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-7 · Cited by 47
“However, this might be challenging since PTP activation may involve disruption of protein-protein interactions which are difficult to break by low molecular weight compounds [24].”
BackgroundTargeting Protein-Protein Interactions for Drug Discovery
Fry, D. C. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2425-7_6 · Cited by 45
Hu, G., Li, X., Zhang, X., Li, Y., Ma, L., Yang, L., Liu, G., Li, W., Huang, J. Y., Shen, X., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301226a · Cited by 42
A nanobody modulates the p53 transcriptional program without perturbing its functional architecture
Bethuyne, J., De Gieter, S., Zwaenepoel, O., Garcia-Pino, A., Durinck, K., Verhelle, A., Hassanzadeh-Ghassabeh, G., Speleman, F., Loris, R., & Gettemans, J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku962 · Cited by 44
“As small molecule drug design is supported by structural biology, the co-crystal structure of Nb3 in complex with the DBD could help identify the crucial binding site or help generate hypotheses for structure-based design for new p53 re-activating compounds (54).”
BackgroundScott, D. E., Coyne, A. G., Venkitaraman, A. R., Blundell, T. L., Abell, C., & Hyvönen, M. (2014) · ChemMedChem · doi:10.1002/cmdc.201402428 · Cited by 43
In silico design of tubulin-targeted antimitotic peptides
Pieraccini, S., Saladino, G., Cappelletti, G., Cartelli, D., Francescato, P., Speranza, G., Manitto, P., & Sironi, M. (2009) · Nature Chemistry · doi:10.1038/nchem.401 · Cited by 44
“, a few encouraging results have been obtained in designing molecules that target PPI”
BackgroundMoon, H., & Lim, H. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.10.023 · Cited by 45
Ligand Discovery Using Small Molecule Microarrays
He, X. G., Gerona‐Navarro, G., & Jaffrey, S. R. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.076943 · Cited by 42
“This concept is supported by structural and thermodynamic studies of ligand-protein interactions (Arkin and Wells, 2004).”
BackgroundGonzález-Pérez, V., Reiner, D. J., Alan, J. K., Mitchell, C., Edwards, L. J., Khazak, V., Der, C. J., & Cox, A. D. (2010) · Journal of Molecular Signaling · doi:10.1186/1750-2187-5-2 · Cited by 42
“33 tractable binding site for drug design (Arkin and Wells, 2004).”
BackgroundInfluentialHong, S.-H., Youbi, S. E., Hong, S. P., Kallakury, B., Monroe, P. J., Erkizan, H. V., Barber-Rotenberg, J. S., Houghton, P. J., Üren, A., & Toretsky, J. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1495 · Cited by 47
“In particular, small molecule inhibitors of protein-protein interactions may only achieve effective concentrations in the micromolar range [19].”
Conformational averaging in structural biology: issues, challenges and computational solutions
Kruschel, D., & Zagrovic, B. (2009) · Molecular BioSystems · doi:10.1039/b917186j · Cited by 43
Model Membrane Platforms for Biomedicine: Case Study on Antiviral Drug Development
Jackman, J. A., & Cho, N. (2012) · Biointerphases · doi:10.1007/s13758-011-0018-2 · Cited by 42
Small‐Molecule and Peptide Inhibitors of the Pro‐Survival Protein Mcl‐1
Beekman, A. M., & Howell, L. A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500497 · Cited by 45
Yang, C., Wang, W., Chen, L., Liang, J., Lin, S., Lee, M.-Y., Ma, D., & Leung, C. (2016) · Chemical Communications · doi:10.1039/c6cc04938a · Cited by 42
Wang, Y., Ueda, M., Wang, X., Han, Z., & Maruoka, K. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.02.079 · Cited by 43
Energy based approach for understanding the recognition mechanism in protein–protein complexes
Gromiha, M. M., Yokota, K., & Fukui, K. (2009) · Molecular BioSystems · doi:10.1039/b904161n · Cited by 45
Druggability predictions: methods, limitations, and applications
Barril, X. (2012) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1134 · Cited by 46
Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53–HDM2 Protein–Protein Interaction
Fischer, P. M. (2006) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-006-9016-5 · Cited by 48
“Exploitation of adventitious allosteric sites, present in individual members of protein conformational ensembles, is another powerful new concept in PPI inhibitor design (Arkin and Wells, 2004).”
BackgroundIdentification of Hot-Spot Locations in Proteins Using Digital Filters
Ramachandran, P., & Antoniou, A. (2008) · IEEE Journal of Selected Topics in Signal Processing · doi:10.1109/jstsp.2008.923850 · Cited by 42
Broad Distribution of Energetically Important Contacts across an Extended Protein Interface
Johnson, L. M., Horne, W. S., & Gellman, S. H. (2011) · Journal of the American Chemical Society · doi:10.1021/ja203358t · Cited by 41
Andreotti, V., Ciribilli, Y., Monti, P., Bisio, A., Lion, M., Jordan, J., Fronza, G., Menichini, P., Resnick, M. A., & Inga, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020643 · Cited by 57
“However, the identification of chemicals that could disrupt protein:protein interactions or protein:DNA interactions involving p53 has proven challenging [24].”
BackgroundProline-Rich Sequence Recognition Domains (PRD): Ligands, Function and Inhibition
Freund, C., Schmalz, H., Sticht, J., & Kühne, R. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-72843-6_17 · Cited by 47
DNA-encoded chemical libraries of macrocycles
Connors, W. H., Hale, S. P., & Terrett, N. K. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.02.004 · Cited by 41
Foster, T. J., MacKerell, A. D., & Guvench, O. (2012) · Journal of Computational Chemistry · doi:10.1002/jcc.23026 · Cited by 42
Araghi, R. R., Ryan, J. A., Letai, A. G., & Keating, A. E. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01002 · Cited by 49
Protein–Protein Interaction Inhibition (2P2I)-Oriented Chemical Library Accelerates Hit Discovery
Milhas, S., Raux, B., Betzi, S., Derviaux, C., Roche, P., Restouin, A., Basse, M.-J., Rebuffet, E., Lugari, A., Badol, M., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00286 · Cited by 44
Heterotrimeric G Proteins as Therapeutic Targets in Drug Discovery
Li, J., Yang, G., Huang, J.-X., Strømgaard, K., Zhang, X., & Xiong, X. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01452 · Cited by 44
Genetics in Light of Transcriptional Adaptation
Kontarakis, Z., & Stainier, D. Y. R. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.08.008 · Cited by 47
“Small molecules can bind to enzymes or receptors and block their function [8], and antisense oligonucleotides can bind to and degrade RNA molecules, or inhibit their translation or splicing [9–12].”
BackgroundChen, S., & Zacharias, M. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00003 · Cited by 44
Yılmaz, E. M., & Güntert, P. (2015) · Journal of Biomolecular NMR · doi:10.1007/s10858-015-9959-y · Cited by 41
“NMR spectroscopy is excellently suited for studying protein–ligand interactions and for discovering high-affinity ligands for proteins (Arkin and Wells 2004), e.”
Bisson, M. M. A., & Groth, G. (2015) · Molecular Plant · doi:10.1016/j.molp.2015.03.014 · Cited by 41
“Similar IC50 values have been described for other small molecule compounds inhibiting the interaction between Interleukin-2 and its receptor protein IL-2R (Braisted et al., 2003; Arkin and Wells, 2004).”
Probing backbone hydrogen bonding in PDZ/ligand interactions by protein amide-to-ester mutations
Pedersen, S. W., Pedersen, S. B., Anker, L., Hultqvist, G., Kristensen, A. S., Jemth, P., & Strømgaard, K. (2014) · Nature Communications · doi:10.1038/ncomms4215 · Cited by 41
“All experimental traces followed single exponential kinetics, and observed rate constants were plotted versus the concentration of C-terminal peptide or nNOS-PDZ and fitted to the following equation (1) to obtain the association rate constant kon and the dissociation rate constant koff.”
MethodCorradi, V., Mancini, M., Santucci, M. A., Carlomagno, T., Sanfelice, D., Mori, M., Vignaroli, G., Falchi, F., Manetti, F., Radi, M., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.011 · Cited by 41
Abdelhamid, H. N., & Wu, H. (2014) · RSC Advances · doi:10.1039/c4ra07638a · Cited by 41
Monti, A., Vitagliano, L., Caporale, A., Ruvo, M., & Doti, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097842 · Cited by 45
“, the residues mainly involved in the interaction and conferring most of the binding energy [83,84].”
BackgroundAndrogen receptor molecular biology and potential targets in prostate cancer
Wilson, E. M. (2010) · Therapeutic Advances in Urology · doi:10.1177/1756287210372380 · Cited by 47
“The interaction between the carboxyl-terminal MAGE-11 F-box and AR NH2-terminal FXXLF motif, where both are predicted to form an a-helical structure, may be amenable to inhibition by drug-like compounds [Askew et al. 2009; Bai et al. 2005; Arkin and Wells, 2004].”
BackgroundMethodUtility of network integrity methods in therapeutic target identification
Peng, Q., & Schork, N. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00012 · Cited by 41
“Since it is known that some cancer-related genes and proteins are difficult to target with small molecules, for example the p53 gene, drugs targeting an edge/interaction for which such genes are connected may offer ways of indirectly targeting and influencing those genes (Arkin and Wells, 2004).”
Backgroundde Souza-Fagundes, E. M., Frank, A. O., Feldkamp, M. D., Dorset, D. C., Chazin, W., Rossanese, O. W., Olejniczak, E. T., & Fesik, S. W. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.11.025 · Cited by 40
“Traditionally, these large, sometimes relatively flat interaction surfaces have a reputation of being very difficult to disrupt with small molecule inhibitors [8].”
BackgroundSelective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity
Hennessy, E. J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.032 · Cited by 44
Zhong, M., Lynch, A. J., Muellers, S. N., Jehle, S., Luo, L., Hall, D. R., Iwase, R., Carolan, J. P., Egbert, M. E., Wakefield, A., et al. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00943 · Cited by 40
Orita, M., Ohno, K., Warizaya, M., Amano, Y., & Niimi, T. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-381274-2.00015-7 · Cited by 47
Roman, D. L., Blazer, L. L., Monroy, C. A., & Neubig, R. R. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.063388 · Cited by 40
Roman, D. L., Ota, S., & Neubig, R. R. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109336590 · Cited by 40
Reversible Modes of Inhibitor Interactions with Enzymes
(2013) · Wiley eBooks · doi:10.1002/9781118540398.ch3 · Cited by 40
Recent Advances in Multicomponent Reaction Chemistry
Hulme, C., Ayaz, M., Martinez‐Ariza, G., Medda, F., & Shaw, A. Y. (2015) · Wiley eBooks · doi:10.1002/9781118771723.ch6 · Cited by 43
Cheng, J., Zhou, J., Kong, L., Wang, H., Zhang, Y., Wang, X., Liu, G., & Chu, Q. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00487b · Cited by 42
New Approaches for Antiviral Targeting of HIV Assembly
Prevelige, P. E. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.074 · Cited by 45
Shavkunov, A. S., Panova, N. I., Prasai, A., Veselenak, R. L., Bourne, N., Stoilova‐McPhie, S., & Laezza, F. (2012) · Assay and Drug Development Technologies · doi:10.1089/adt.2011.413 · Cited by 39
“Constructs expressing the CLuc (398–550) and NLuc (2-415) fragments of firefly Photinus pyralis luciferase were fused, respectively, to full-length FGF14 and a chimera of the transmembrane protein CD4 and the Cterminal tail of Nav1.”
MethodTranscription factors and chromatin proteins as therapeutic targets in cancer
Johnston, S. J., & Carroll, J. S. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.02.002 · Cited by 52
Reddy, T. R. K., Li, C., Fischer, P. M., & Dekker, L. V. (2012) · ChemMedChem · doi:10.1002/cmdc.201200107 · Cited by 40
Protein surface recognition by calixarenes
Zadmard, R., & Alavijeh, N. S. (2014) · RSC Advances · doi:10.1039/c4ra05181e · Cited by 45
Aptamers as Valuable Molecular Tools in Neurosciences
Wolter, O., & Mayer, G. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1969-16.2017 · Cited by 47
“…enzyme is laborious and expensive and thus unlikely to keep pace with the demands of the fast-growing systems biology field, which identifies novel potential target proteins or whose characterization the rapid availability of potent and specific inhibitors will be essential (Arkin and Wells, 2004).”
BackgroundJoce, C., Stahl, J. A., Shridhar, M., Hutchinson, M. R., Watkins, L. R., Fedichev, P. O., & Yin, H. H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.103 · Cited by 42
The homeobox gene Mohawk represses transcription by recruiting the sin3A/HDAC co‐repressor complex
Anderson, D. M., Beres, B. J., Wilson‐Rawls, J., & Rawls, A. (2009) · Developmental Dynamics · doi:10.1002/dvdy.21873 · Cited by 47
Ehrmann, F. R., Stojko, J., Metz, A., Debaene, F., Barandun, L. J., Heine, A., Diederich, F., Cianférani, S., Reuter, K., & Klebe, G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175723 · Cited by 39
“It is known that entropy-driven binders lead to difficulties in ITC measurements [35].”
BackgroundMolecular targeting of angiogenesis for imaging and therapy
Brack, S., Dinkelborg, L. M., & Neri, D. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1648-0 · Cited by 44
Peptide segments in protein-protein interfaces
Pal, A., Chakrabarti, P., Bahadur, R. P., Rodier, F., & Janin, J. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0010-7 · Cited by 44
“J. Biosci. 32(1), January 2007 atoms have also been incorporated in an indirect manner in the defi nition of the two parameters in fi gure 7. The control of protein-protein interactions is believed to be the next frontier in pharmaceuticals (Toogood 2002; Arkin and Wells 2004 ) for designing peptides aimed at inhibiti…”
BackgroundUltra-weak reversible protein–protein interactions
Rowe, A. J. (2011) · Methods · doi:10.1016/j.ymeth.2011.02.006 · Cited by 38
Unravelling Hot Spots: a comprehensive computational mutagenesis study
Moreira, I. S., Fernandes, P. A., & Ramos, M. J. (2006) · Theoretical Chemistry Accounts · doi:10.1007/s00214-006-0151-z · Cited by 38
Differential Impact of β and γ Residue Preorganization on α/β/γ-Peptide Helix Stability in Water
Shin, Y., Mortenson, D. E., Satyshur, K. A., Forest, K. T., & Gellman, S. H. (2013) · Journal of the American Chemical Society · doi:10.1021/ja403319q · Cited by 41
Assessing the druggability of protein-protein interactions by a supervised machine-learning method
Sugaya, N., & Ikeda, K. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-263 · Cited by 40
“Such PPIs were carefully selected from review articles focusing on drugga-ble PPIs [1-7].”
BackgroundInfluentialFoldamers in Medicinal Chemistry
Pasco, M., Dolain, C., & Guichard, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12565-x · Cited by 44
Yasui, T., Yamamoto, T., Sakai, N., Asano, K., Takai, T., Yoshitomi, Y., Davis, M., Takagi, T., Sakamoto, K., Sogabe, S., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.07.037 · Cited by 41
Paul, A., Viswanathan, G. K., Mahapatra, S., Balboni, G., Pacifico, S., Gazit, E., & Segal, D. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00123 · Cited by 41
Lee, E. F., Sadowsky, J., Smith, B. J., Czabotar, P. E., Peterson‐Kaufman, K. J., Colman, P. M., Gellman, S. H., & Fairlie, W. D. (2009) · Angewandte Chemie · doi:10.1002/ange.200805761 · Cited by 39
Targeting Transcription Factors in Cancer: From “Undruggable” to “Druggable”
Tao, Z., & Wu, X. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2815-7_9 · Cited by 43
Thakur, A., Manohar, S., Gerena, C. E. V., Zayas, B., Kumar, V., Malhotra, S. V., & Rawat, D. S. (2014) · MedChemComm · doi:10.1039/c3md00399j · Cited by 38
Inhibition of Salmonella enterica Biofilm Formation Using Small-Molecule Adenosine Mimetics
Koopman, J. A., Marshall, J. M., Bhatiya, A., Eguale, T., Kwiek, J. J., & Gunn, J. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03407-14 · Cited by 42
“Small-molecule inhibitors are of great interest and are being explored for their ability to interrupt intracellular signal transduction and protein-protein interactions, as a method to disrupt processes necessary for virulence (32).”
BackgroundLong-Distance FRET Analysis: A Monte Carlo Simulation Study
Bojarski, P., Kułak, L., Walczewska-Szewc, K., Synak, A., Marzullo, V. M., Luini, A., & D’Auria, S. (2011) · The Journal of Physical Chemistry B · doi:10.1021/jp202152m · Cited by 38
Randino, R., Grimaldi, M., Persico, M., Santis, A. D., Cini, E., Cabri, W., Riva, A., D’Errico, G., Fattorusso, C., D’Ursi, A. M., et al. (2016) · Scientific Reports · doi:10.1038/srep38846 · Cited by 42
PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Dev, K. K. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607779318343 · Cited by 39
“PDZ domain-motif interaction ‘hotspots’ may accordingly represent good sites for binding small molecular weight ligands [226].”
BackgroundInfluentialβ‐Strand Mimetic Foldamers Rigidified through Dipolar Repulsion
German, E. A., Ross, J. E., Knipe, P. C., Don, M. F., Thompson, S., & Hamilton, A. D. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410290 · Cited by 40
Na, Z., Pan, S., Uttamchandani, M., & Yao, S. Q. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201405169 · Cited by 40
ATP-noncompetitive CDK inhibitors for cancer therapy: an overview
Abate, A. A., Pentimalli, F., Esposito, L., & Giordano, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.798641 · Cited by 47
Enzyme Inhibition by Allosteric Capture of an Inactive Conformation
Lee, G., Shahian, T., Baharuddin, A., Gable, J. E., & Craik, C. S. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.06.032 · Cited by 37
“3–6 As a result, PPIs have gained more traction as targets for therapeutics.(7,8) Until recently, the most successful mediators of PPIs had been antibody or peptide based.”
BackgroundMaurer, C. K., Fruth, M., Empting, M., Avrutina, O., Hoßmann, J., Nadmid, S., Gorges, J., Herrmann, J. E., Kazmaier, U., Dersch, P., et al. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0033 · Cited by 37
“This cannot be taken for granted given the large interaction interfaces lacking well-defined binding pockets - a scenario, which is usually encountered with macromolecule-macromolecule interactions [53].”
Recent advances in 1,2,4-triazolo[1,5-a]pyrimidine chemistry
Fischer, G. (2019) · Advances in heterocyclic chemistry · doi:10.1016/bs.aihch.2018.10.002 · Cited by 37
Wolter, M., Valenti, D., Cossar, P. J., Hristeva, S., Levy, L. M., Genski, T., Hoffmann, T., Brunsveld, L., Tzalis, D., & Ottmann, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00401 · Cited by 42
The Relationship between Oligomeric State and Protein Function
Griffin, M. D. W., & Gerrard, J. A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3229-6_5 · Cited by 45
Maulik, U., Mukhopadhyay, A., Bhattacharyya, M., Kaderali, L., Brors, B., Bandyopadhyay, S., & Eils, R. (2012) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2012.139 · Cited by 37
Knauer, S. K., & Stauber, R. H. (2005) · Analytical Chemistry · doi:10.1021/ac050413o · Cited by 37
Synthetic turn mimetics and hairpin nucleators: Quo Vadimus?
Nair, R. V., Baravkar, S. B., Ingole, T. S., & Sanjayan, G. J. (2014) · Chemical Communications · doi:10.1039/c4cc03114h · Cited by 38
Monitoring 14-3-3 Protein Interactions with a Homogeneous Fluorescence Polarization Assay
Du, Y., Masters, S. C., Khuri, F. R., & Fu, H. (2006) · SLAS DISCOVERY · doi:10.1177/1087057105284862 · Cited by 37
“Although protein-protein interactions are generally difficult to disrupt, recent studies have yielded some successes, such as small-molecule inhibitors for the MDM2/p53 interaction and the Smac/XIAP association.(18-20) In support of the strategy to target 14-3-3 proteins with a small molecule, a single”
Background
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.